Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma
Christelle Bouchart(Université Libre de Bruxelles), Jean‐Luc Van Laethem(Deventer Ziekenhuis), Jean Closset(Erasmus Hospital), Jean-Luc Engelholm(Université Libre de Bruxelles), Matthieu Hein(Université Libre de Bruxelles), Patrizia Loi(Université Libre de Bruxelles), Luigi Moretti(Université Libre de Bruxelles), Julie Navez(Université Libre de Bruxelles), Laura Mans(Université Libre de Bruxelles), Alain Hendlisz(London Cancer), Pierre Eisendrath(Centre Hospitalier de l’Université de Montréal), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Dirk Van Gestel(Université Libre de Bruxelles), Yeter Gökburun(Centre Hospitalier Régional de Namur), Thierry De Grez(Centre Hospitalier Régional de Namur)
Cited by 29
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study
|The Lancet Oncology|2014|727
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
|Journal of Crohn s and Colitis|2013|669